Cebix is developing Ersatta™, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes. Ersatta is a long-acting form of C-peptide that, unlike other products simply directed at symptomatic relief, has the potential to reverse the chronic complications of diabetes. Cebix is evaluating Ersatta in a Phase 2 clinical trial in patients with type 1 diabetes.
Type 1 and some type 2 diabetic patients have a C-peptide deficiency, which can cause a reduction in microvascular circulation, resulting in progressive damage to the nerves, retina and kidneys. This damage contributes to the onset of peripheral neuropathy, retinopathy, nephropathy and autonomic neuropathy, all chronic, long-term complications of diabetes. There are currently few treatment options for these complications of diabetes, and there are no approved drugs to treat the microvascular damage.
Specialties
Diabetes Complications, Replacement Therapies, Peripheral Neuropathy, Retinopathy, Nephropathy, Autonomic Neuropathy
Cebix, Inc. Activity on LinkedIn
-
Cebix, Inc. added a new product: Ersatta
